EVOK Stock Recent News Evoke Pharma Inc (EVOK) 6.70 11/09/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Evoke Pharma Inc (EVOK) 6.70 $EVOK

Evoke Pharma Schedules Webcast and Conference Call for Third Quarter 2014 Financial Results
GlobeNewswire - Thu Nov 06, 7:42AM CST
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the Third Quarter of 2014 on Thursday, November 13, 2014, after the close of the market.
EVOK: 6.70 (+0.08)

Nasdaq stocks posting largest percentage increases
AP - Thu Oct 30, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
IMDZ: 30.06 (-0.03), ABMD: 32.13 (+0.47), BGFV: 12.95 (+0.27), RDCM: 8.80 (+0.12), AMED: 24.79 (-0.38), MRCY: 13.51 (-0.18), OMER: 17.37 (+0.09), ESBF: 18.66 (+0.03), EVOK: 6.70 (+0.08), IQNT: 17.14 (-0.14), KONA: 22.76 (-0.03), TQNT: 22.07 (-0.82), LAKE: 13.29 (+0.42), SAJA: 5.79 (-0.61)

Evoke Pharma completes enrollment of ECG Study of EVK-001 for diabetic gastroparesis ahead of schedule
M2 - Wed Sep 10, 6:22AM CDT
Pharmaceutical company Evoke Pharma (NasdaqCM:EVOK) disclosed on Tuesday that it has completed the enrollment in its thorough ECG (electrocardiogram) (QT) study of its lead product candidate EVK-001.
EVOK: 6.70 (+0.08)

Evoke Pharma Announces the Completion of Enrollment in Its Thorough ECG Study for EVK-001
GlobeNewswire - Tue Sep 09, 7:30AM CDT
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has completed enrollment in its thorough ECG (QT) study of EVK-001, the Company's lead product candidate. EVK-001 is currently in a Phase 3 clinical trial for the relief of symptoms associated with acute and recurrent gastroparesis in women with diabetes mellitus.
EVOK: 6.70 (+0.08)

Evoke Pharma to Present at the Aegis Capital Corp. 2014 Healthcare & Technology Conference
GlobeNewswire - Thu Sep 04, 7:35AM CDT
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that Dave Gonyer, CEO, will present a corporate overview at the Aegis Capital Corp. 2014 Healthcare & Technology Conference, being held September 10-13, 2014 at The Encore at The Wynn in Las Vegas, Nevada. The Company is scheduled to present on Thursday, September 11, 2014 at 2:00pm PT. A copy of the corporate overview will be posted to the company's website following the presentation.
EVOK: 6.70 (+0.08)

Evoke Pharma Reports Second Quarter 2014 Results
GlobeNewswire - Wed Aug 13, 3:01PM CDT
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the second quarter ended June 30, 2014.
EVOK: 6.70 (+0.08)

Evoke Pharma Announces Initiation of a Thorough ECG (QT) Study for EVK-001
GlobeNewswire - Tue Aug 12, 4:42PM CDT
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the initiation of its thorough ECG (QT) study of the Company's lead product candidate, EVK-001, which is currently in a Phase 3 clinical trial for the relief of symptoms associated with acute and recurrent gastroparesis in women with diabetes mellitus.
EVOK: 6.70 (+0.08)

Nasdaq stocks posting largest volume decreases
AP - Tue Aug 05, 5:06PM CDT
NEW YORK (AP) — A look at the 10 biggest volume decliners on Nasdaq at the close of trading:
MCBK: 19.14 (+0.08), EVOK: 6.70 (+0.08), SBBX: 10.00 (-0.05), THRD: 40.87 (-1.08), NECB: 6.98 (+0.03), CBIN: 26.50 (-0.25), AMIC: 10.40 (-0.35), BRID: 7.75 (-0.50), SLTC: 5.84 (-0.20)

Evoke Pharma Schedules Webcast and Conference Call for Second Quarter 2014 Financial Results
GlobeNewswire - Wed Jul 30, 7:40AM CDT
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the second quarter of 2014 on Wednesday, August 13, 2014, after the close of the market.
EVOK: 6.70 (+0.08)

Evoke Pharma Reports Fourth Quarter and Year End 2013 Results
GlobeNewswire - Tue Mar 25, 3:30PM CDT
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the fourth quarter and year ended December 31, 2013.
EVOK: 6.70 (+0.08)

Evoke Pharma Schedules Webcast and Conference Call for Fourth Quarter 2013 Financial Results
GlobeNewswire - Mon Mar 10, 9:02AM CDT
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it will issue its financial results for the Fourth Quarter of 2013 on Tuesday, March 25, 2014, after the close of the market.
EVOK: 6.70 (+0.08)

Evoke Pharma to Present at 26th Annual ROTH Conference
GlobeNewswire - Tue Mar 04, 7:30AM CST
Evoke Pharma, Inc. (Nasdaq:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that its President and Chief Executive Officer, Dave Gonyer, R.Ph., will be presenting at the 26 Annual ROTH Conference, being held March 10-12, 2014 at the Ritz-Carlton in Dana Point, California.
EVOK: 6.70 (+0.08)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Aker Solutions Lands Big Role in Qatar Oil Upgrade

Updated Category News Views 88

Qatari Venture Beckons Aker Solutions Well, it's not every day you hear about a decades-old oil field getting a facelift, and yet here we are. Aker Solutions has received a nod of approval with a letter of award from PTSC Mechanical and Construction Limited Company (PTSC M&C). This gig is all about the Maydan Mahzam oil field way off the Qatari coast—a legacy site...

Continue Reading
Silvercorp Navigates Q2 with Strategic Resilience

Updated Category News Views 0

Silvercorp's Q2: A Mixed Bag of Gains and Strains Coming in hot this November, Silvercorp swings between highs and lows for Q2 Fiscal 2027. They reported a not-too-shabby adjusted net income of $18.4 million—or $0.08 a pop per share. No one's throwing a parade for that, but it's stable sailing amidst some choppy waters. Safety Comes with a Price Safety upgrades have...

Continue Reading
TI's New Modules Transform Factory Networks

Updated Category News Views 101

Pioneering Solutions for Modern Factories Texas Instruments (TI) just rolled out some shiny new toys that promise to make a splash in the world's factory floors. We're talking about two key pieces—the TICS100MOD system-on-module (SoM) and the TIOM2212 IO-Link master—that are set to redefine how factories handle Industrial Ethernet connections. You won't hear this from...

Continue Reading
FirstService Jolts Mira Mar Redesign Masterplan

Updated Category News Views 30

Sarasota's Mira Mar Finds Its Match Holy smokes! Sarasota's making waves again as Mira Mar, the high-end luxury condominium development, ropes in FirstService Residential to give it that extra oomph. Now, we're talkin’ about a real shake-up in downtown Sarasota real estate. The game here isn’t just grabbing a slice of the pie; it's the whole damn pie. Luxury Living...

Continue Reading
Mondego Bio Charges Ahead with Cancer Therapy Trials

Updated Category News Views 78

Cracking Cancer's Code: Mondego's Bold Move Big news from Portugal today—a quiet town called Cantanhede is now the epicenter of a potential game-changer in cancer therapy. Mondego Bio, with its small-molecule innovator MB?388, is diving headfirst into a Phase 1 clinical study. If you're scratching your head about the significance, let me spell it out: this is an attempt...

Continue Reading
Veterans Day Deals Expand with App Launch and Giveaway

Updated Category News Views 82

A Salute with Savings: Veterans Day Unveiled Every year, when November rolls around, the echoes of gratitude pour in across the nation, morphing into tangible gestures—from free meals to hefty discounts for those who've donned the uniform. Expected or not, these gestures hold weight beyond dollars. Come November 11, The Military Wallet is back with its sizable list of...

Continue Reading
Fosun's Strategic Innovations Unveiled at CIIE 2026

Updated Category News Views 129

Fosun's Nine-Year CIIE Journey Fosun's been trotting out its innovations at the China International Import Expo (CIIE) for nine straight years. With 162 countries in the mix this time around, they're not just playing house—it’s downright world-class boasting. Fosun’s rolling out their hard-hitters in the medical tech space, showing they’re no rookies to the...

Continue Reading
GAC Hits Record with 223,000 Units Exported in 2026

Updated Category News Views 88

GAC Gaining Ground Globally in 2026 China's GAC is making waves with its recent export figures. They've blitzed past the competition, exporting 223,000 units from January to October 2026. That's not just a number, it’s a record, with October alone seeing a hefty 26,017 units shipped—marking an impressive 80.8% growth compared to last year. A Strategic Push in Europe...

Continue Reading
Algorized's AFM: A New Era for Human-Machine Interaction

Updated Category News Views 104

Breaking Ground with Innovative Tech at CIIE 2026 When it comes to understanding human movement and biology, Algorized is rewriting the rules. Their Algorized Foundation Model (AFM) is strutting its stuff at the China International Import Expo 2026 (CIIE) in Shanghai, showcasing a whole new level of human-machine interaction that transcends mere technological wizardry....

Continue Reading
Multi-Society Panel Boosts Vaccine Guidance Clarity

Updated Category News Views 66

Vaccination Confusion: Could Clarity Finally Be Here? Here's the scoop, folks. In the swirling mess of immunization advice, a coalition of top medical societies has thrown a lifeline to clinicians. If you're drowning in conflicting vaccine guidance, this panel's unified stance might just be your life raft. The Coalition Forces of Immunization We have the Vaccine Guidance...

Continue Reading

Top 5 Most Recently Viewed Articles

Oncoinvent Moves Forward with Phase 2 Ovarian Cancer Trial

Updated Category News Views 196

Oncoinvent Advances Phase 2 Trial of Radspherin in Ovarian Cancer Oncoinvent, a forward-thinking radiopharmaceutical company, has made significant strides in tackling ovarian cancer. Recently, they revealed that the first patient has been dosed in the pivotal Phase 2 clinical trial of Radspherin, a targeted alpha-radiation therapy aimed at addressing peritoneal...

Continue Reading
Neogen Corp. Projects Strong Future Amidst Market Challenges

Updated Category News Views 170

Neogen Corp. Shows Resilience with Positive Financial Forecast Neogen Corp. (NASDAQ: NEOG) has shown solid performance recently, igniting interest among investors with its better-than-expected financial reports. Despite ongoing challenges in the market, the company is committed to its annual forecast, which bodes well for its future. Quarterly Earnings Reflect Stability...

Continue Reading
Significant Oil Discovery at Bourdon Prospect Boosts BW Energy

Updated Category News Views 397

Major Oil Discovery at Bourdon Prospect by BW Energy BW Energy has made an exciting announcement regarding a significant oil discovery at the Bourdon prospect located in the Dussafu Licence offshore Gabon. This finding not only highlights the company’s growth potential but also adds valuable reserves to its portfolio. Details of the Oil Discovery The exploration and...

Continue Reading
Baha Mar's FUZE Art Fair Welcomes Art Enthusiasts for Free

Updated Category News Views 176

Baha Mar's Exciting Extension of the FUZE Caribbean Art Fair Baha Mar, the Caribbean's premier integrated luxury resort, is thrilled to announce the return of the FUZE Caribbean Art Fair as part of the upcoming Bahamas Culinary & Arts Festival. This year's event offers a remarkable opportunity for art enthusiasts with complimentary admission to FUZE from October 23-25,...

Continue Reading
R3 Foundation to Launch Corda Protocol for Yield Curators

Updated Category News Views 91

Introduction to the Corda Protocol Launch R3 Foundation is poised to introduce the Corda protocol, a promising initiative designed to revolutionize the yield space within the Solana ecosystem. This protocol represents a strategic blend of decentralized finance (DeFi) and traditional finance (TradFi), aiming to bridge the gap effectively. Corda protocol is tailored to...

Continue Reading